|
gptkbp:instance_of
|
gptkb:vaccine
|
|
gptkbp:accessories
|
multiple countries
|
|
gptkbp:approves
|
gptkb:United_Arab_Emirates
Chinese National Medical Products Administration
|
|
gptkbp:average_temperature
|
2 to 8 degrees Celsius
|
|
gptkbp:clinical_trial
|
over 40,000
Phase III
published in medical journals
China, UAE, Bahrain, Egypt
|
|
gptkbp:community_health
|
gptkb:significant
|
|
gptkbp:developed_by
|
gptkb:China_National_Pharmaceutical_Group
|
|
gptkbp:dosage_form
|
recommended after initial series
two doses
|
|
gptkbp:emergency_services
|
gptkb:WHO
|
|
gptkbp:first_use_date
|
December 2020
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sinopharm
|
|
gptkbp:is_effective_against
|
79%
|
|
gptkbp:is_vulnerable_to
|
gptkb:complex
global
conditional
ongoing
affordable
mixed
varies by country
continuous
rapid
logistical issues
varies by population
government and private sector
inactivated virus technology
subunit vaccine
standard refrigeration
ongoing post-marketing surveillance
monitored globally
|
|
gptkbp:manufacturer
|
gptkb:Sinopharm_Group
|
|
gptkbp:marketed_as
|
over 50 countries
|
|
gptkbp:partnerships
|
international organizations
|
|
gptkbp:route_of_administration
|
intramuscular
|
|
gptkbp:safety_features
|
generally safe
|
|
gptkbp:side_effect
|
mild pain at injection site
|
|
gptkbp:target_audience
|
adults and children over 3 years old
|
|
gptkbp:type
|
inactivated virus vaccine
|
|
gptkbp:used_for
|
gptkb:COVID-19
|
|
gptkbp:vaccine_clinical_data
|
extensive
|
|
gptkbp:vaccine_distribution_network
|
established
|
|
gptkbp:vaccine_global_impact
|
gptkb:significant
|
|
gptkbp:wholisting
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Ali_Health
gptkb:China_National_Pharmaceutical_Group_Corporation
|
|
gptkbp:bfsLayer
|
5
|